What management is recommended for an elevated platelet count of 610 × 10⁹/L following an intravenous iron infusion?

Management of Platelet Count 610 × 10⁹/L After IV Iron Infusion

A platelet count of 610 × 10⁹/L following IV iron infusion represents reactive thrombocytosis from iron deficiency anemia and requires monitoring only—no treatment is needed, as this will resolve spontaneously with continued iron repletion.

Understanding the Clinical Context

This elevated platelet count is a reactive thrombocytosis secondary to iron deficiency, not a complication of the IV iron itself. Iron deficiency anemia commonly causes elevated platelet counts, and you're observing the tail end of this phenomenon 1.

Expected Timeline of Platelet Normalization

The research demonstrates a clear pattern of platelet decline after iron repletion:

• Within 2 weeks: 50% of patients with thrombocytosis (platelets >450 × 10⁹/L) normalize 1
• Within 6 weeks: All patients with IDA-induced thrombocytosis resolve to <450 × 10⁹/L 1
• Mean decrease: Expect a 16-27 × 10⁹/L reduction in platelet count following iron replacement 2, 3

At 610 × 10⁹/L, your patient falls into the moderate thrombocytosis range and should follow this predictable downward trajectory.

Recommended Management Algorithm

Immediate Actions (Now)

1. Continue iron therapy as planned—do not discontinue 1
2. No antiplatelet or anticoagulation therapy is indicated for reactive thrombocytosis alone
3. Document baseline thrombotic risk factors: smoking, obesity, immobility, malignancy, prior thrombosis

Follow-Up Monitoring

Recheck CBC in 2-4 weeks to confirm expected platelet decline 4, 1:

• If platelets declining → continue iron therapy, recheck at 6-8 weeks with iron parameters
• If platelets stable or rising after 6 weeks → investigate for alternative causes (see below)

At 4-8 weeks post-final infusion 4:

• Complete CBC with iron parameters (ferritin, TSAT)
• Hemoglobin should increase 1-2 g/dL
• Platelets should normalize or trend toward normal

Critical Caveats and Pitfalls

When to Worry About Thrombotic Risk

While reactive thrombocytosis from IDA rarely causes thrombosis, increase monitoring frequency if:

• Platelet count >1000 × 10⁹/L
• Patient has additional prothrombotic risk factors (malignancy, recent surgery, prolonged immobility)
• Symptoms suggesting thrombosis develop (chest pain, leg swelling, neurologic changes)

The evidence shows that iron deficiency itself may increase thrombotic risk through elevated transferrin and platelet counts 3, making iron repletion protective rather than harmful.

Distinguish From True Drug-Induced Thrombocytopenia

Be aware of the rare paradoxical phenomenon: some patients develop transient thrombocytopenia (not thrombocytosis) after IV iron, termed "stem cell steal" 5. This occurs when:

• Severe baseline anemia (Hb <7 g/dL)
• Platelets drop precipitously within days of IV iron
• Self-limited, resolves in 1-2 weeks as erythropoiesis stabilizes

This is the opposite of your scenario but worth recognizing.

When Thrombocytosis Persists Beyond 6 Weeks

If platelets remain >450 × 10⁹/L after 6 weeks of adequate iron repletion, consider 1:

• Concomitant myeloproliferative neoplasm (check JAK2 mutation)
• Ongoing inflammatory process
• Unrecognized chronic blood loss continuing the iron deficiency

What NOT to Do

• Do not stop iron therapy due to elevated platelets—this perpetuates the problem
• Do not start aspirin prophylactically for reactive thrombocytosis alone without other indications
• Do not check iron parameters before 4 weeks post-infusion—results will be spuriously elevated and misleading 4

The Bottom Line

Your patient's platelet count of 610 × 10⁹/L is an expected finding in iron deficiency anemia and will normalize with continued iron repletion. Monitor the CBC in 2-4 weeks to confirm the expected decline, continue iron therapy as planned, and reassess with complete iron parameters at 4-8 weeks post-treatment 4, 1.